Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
NovoCure Limited Q4 2025 Earnings Call Summary [Yahoo! Finance]
Novocure to Participate in 2026 Leerink Global Healthcare Conference
NovoCure (NVCR) had its price target raised by HC Wainwright from $47.00 to $49.00. They now have a "buy" rating on the stock.